Dr. Eva Dahlén holds a position as Global Evaluation Director, Search & Evaluation at Novo Nordisk. In this capacity, she takes a leading role in overseeing and managing partnering activities in diabetes. Eva has several year’s experience in S&E across a range of technology areas, including RNA & gene therapy, oral and alternative delivery of biologics, and AI/ML-enabled target and drug discovery. She has led numerous due diligences, including those leading to partnerships with Ascendis Pharma and Valo Health. Prior to Novo Nordisk, Eva held various positions in business development and R&D at the immuno-oncology company, Alligator Bioscience. She has a scientific background in immunology and oncology and holds a Ph.D. in immunology.

Andreas Dirnagl is the Head of Healthcare Strategy and Senior Client Advisor at DNB Bank, bringing more than 30 years of experience across corporate banking, equity research, and financial advisory in the healthcare sector. Based in New York, he advises clients across life sciences and healthcare, supporting global market strategies and cross-border expansion.

Dirnagl began his career in corporate banking at Deutsche Bank, where he helped establish the firm’s inaugural U.S. healthcare strategy. He subsequently transitioned to sell-side equity research covering healthcare, later serving as the Global Head of Healthcare Services Coverage at J.P. Morgan. Prior to joining DNB, Dirnagl spent roughly a decade at MUFG as the Global Head of Healthcare Research and Strategy, leading a coverage expansion that scaled the healthcare business from 40 clients and $60 million annually to more than 140 clients and $270 million.

Anesa Mulabecirovic Sahnoun, MD, PhD, MBA, is a physician and healthcare portfolio manager at DNB Asset Management in Oslo, where she built and leads DNB Fund Women’s Health, the world’s first actively managed global equity fund dedicated to women’s health.

She designed the fund’s investment universe starting with biology: conditions that affect women exclusively, disproportionately or differently. She then mapped listed companies across therapeutics, diagnostics, medical technology, healthcare services and consumer health. Her work centres on where those biological differences translate into durable commercial value in public markets.

Anesa has a clinical background in internal medicine and holds a PhD in medicine from the University of Bergen and King’s College. Her research earned her the EFSUMB Young Investigator Award. She has served on the boards of several European and Norwegian medical societies. Before joining DNB in 2021, she worked in venture capital, investing in healthcare companies.

Farzad’s background is in preclinical and clinical research with drug development experience from US based global pharma in the US and Norway. He has 17 years of experience in commercializing medical/biotech projects from the Sarsia investment system. Farzad received his doctorate in pharmacology from the University of Edinburgh Medical School, UK and postdoctoral training from Haukeland University Hospital Bergen, Norway.

Thomas Michael Thestrup is the founding Managing Director of Fresenius Ventures and joined Fresenius from Angelini Ventures, an international corporate healthcare venture capital company and part of the Italian industrial group Angelini Industries.

Thomas has more than 15 years of experience across research, biotech, healthtech, and the pharma industry. Prior to Angelini Ventures, he held senior business development roles at Lundbeck A/S as Director of Corporate Business Development and Strategy and at UCB Pharma in Global Business Development. He began his investment career at Sunstone Life Science Ventures. Thomas received his Ph.D. from the Max Planck Institute of Neurobiology in Munich.

Cecilia Stureborg von Schéele is CFO of Flerie. She has more than 20 years of experience in finance, including roles at Recipharm and KPMG, and she worked on Viva Wine Group’s IPO. She holds an MSc in International Business Administration from Lund University. She is a board member of Stockholm Cairn and a deputy board member of Binno.

Svana is co-founder and Managing Partner of Frumtak Ventures. She has overseen several internatioanl mergers and acquisitions, and has extensive experience of founding and leading startups. Svana sits on the boards of Tulipop, DataDwell, Sidekick Health, Activity Stream, Abler, and Arctic Trucks.

Pekka is a Founding Partner of Innovestor Life Science, a Nordic VC fund manager investing in transformative early-stage life science and health tech companies. Pekka has spent over 25 years with innovative startups in health and life sciences, including digitalization of data capture in clinical trials, cancer radiotherapy, and as founder and CEO in oncology and CNS drug development companies. Pekka has actively supported health & life science teams as mentor and board member and IPO’d two companies. He loves working with passionate founders who want to change the world for the better.

Stephan has a PhD in Protein Chemistry and immunology from the Technical University of Denmark and UCSF. Stephan has broad executive experience from private as well as public biotech companies with responsibilities for R&D, operations, clinical development and corporate strategy. Stephan was a founding member of the early investment and company creation team Novo Seeds at Novo Holdings and has worked in life science venture capital as an active company creator and early investor for almost 20 years. His investments have mainly focused on the Nordic area, where Stephan has led the creation and funding of more than 30 companies. Stephan is based in Copenhagen.

Renée Aguiar-Lucander is CEO of Hansa Biopharma, a European based commercial stage company with a novel immunomodulatory technology based on a proprietary platform. She joined Hansa in April 2025 and was previously CEO of Calliditas Therapeutics AB, where she successfully built and led the company to achieve the first ever accelerated approval by the cardio renal division of the FDA.  During her tenure, the Company listed on NASDAQ in both Sweden and the U.S. and successfully launched TARPEYO, the first ever approved drug for IgA nephropathy, a rare kidney disease.  The Company had a fully integrated US commercial entity generating product sales in excess of $100m in 2023.  In September 2024, Calliditas was acquired by Asahi Kasei Corporation for over $1bn.  Prior to Calliditas, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior investment roles in Omega Funds and 3i Group. She is a Board member of AC Immune and Inventiva Pharma as well as being a senior advisor to Athyrium Capital Management.

Dr. Lao Saal, MD/PhD, is founder of SAGA Diagnostics (http://sagadiagnostics.com), a 2016 spinout company from Lund University that focuses on circulating tumor DNA (ctDNA) liquid biopsy testing, and which was recently acquired by Foundation Medicine / Roche for up to 595 MUSD.  SAGA’s technologies and simple blood samples are used to risk-stratify patients, monitor response to treatment, and help direct therapeutic choices.  Dr. Saal has MD and PhD degrees from Columbia University (New York) and has trained at the U.S. National Institutes of Health and Memorial Sloan-Kettering Cancer Center, and is currently Co-Director of the CIRCE Women’s Cancer Research Center at Lund University as well as Medical Director of DoMore Diagnostics AS, a AI-powered digital pathology biomarker spinout company with lead product in colorectal cancer.  With a focus on cancer genomics, he has published more than 75 articles, including in leading journals such as Nature Genetics, Science, and PNAS, which in total have been cited more than 15,000 times.

CEO of PainCure Pharma Sweden AB. Martin Jönsson has more than 25 years of experience in the global pharmaceutical industry and has held several executive positions, with experience in business development, marketing, sales, alliance management and medical affairs. Previous employers include Roche and Ferring Pharmaceuticals. Martin has worked internationally, including several years in the USA.

Linda Spahiu Elvesjö is Principal at Sound Bioventures. Before joining Sound Bioventures, she spent four years as an investment manager at Karolinska Development, where she managed deal flow and led investments. During that time, she served as a board member of Henlez, deputy board member of PharmNovo and Chair of the nomination committee of Promimic.

Earlier, Linda was CEO of a Swedish start-up in cancer diagnostics, where she led the company’s work on clinical studies, product development, intellectual property and fundraising. Before that, she worked at the management consultancy Boston Consulting Group, focusing exclusively on medtech and life science projects.

Linda holds an MSc in biotechnology from KTH Royal Institute of Technology and a PhD in enzymology from Karolinska Institutet. She is based in Stockholm.

Kristofer Klerfalk is a Uppsala-based serial entrepreneur and business angel with a strong passion for supporting first-time entrepreneurs. He is a pharmacist, and most of his entrepreneurial career has been connected to healthcare, pharmaceuticals, and medical technology, but in recent years he has also co-founded companies such as Qlerify and the three latest LSI funds; Delta, Epsilon Zeta. Kristofer has extensive board experience from both the business sector and from non-profit organizations and foundations that promote entrepreneurship.

Karl Tobieson has been CEO of Linc since 2020. Before that, he led MedCap from 2008 to 2020, where he is now Chairman of the Board. Earlier in his career he co-ran a corporate finance firm and worked as an investment manager at Centrecourt and Cell Innovation. Karl also serves on the boards of Alder Therapeutics and Melius Pharma. He holds a Master of Science in Mechanical Engineering, specialising in Industrial Economics, from KTH Royal Institute of Technology in Stockholm.

Claus Henrik Johansen is CEO of Global Health Invest. He spent 19 years (2002–2021) at Danske Bank Asset Management as Senior Portfolio Manager, with global responsibility for healthcare investments. He then served as Head of Research and Chief Analytics Officer at Airfinity, a UK health intelligence company focused on infectious and cardiovascular diseases. Over the years Claus has met healthcare companies across Europe and the US, and has built an international investor network spanning hubs such as London, Basel, Boston and New York.

Julie Waras Brogren serves as Chief Executive Officer of Gedea Biotech, bringing more than 20 years of leadership experience across the pharmaceutical, biotech, and medtech sectors. Prior to leading Gedea, she spent six years as Chief Commercial Officer, Deputy CEO, and CFO at Ascelia Pharma, a Malmö-based, Nasdaq-listed company developing orphan oncology therapeutics. Her background also includes serving as President of Canadian medtech company BresoTec, as well as holding key commercial leadership roles and driving global product launches at Novo Nordisk.

Fredrik Meurling is the CEO and a co-founder of Yazen (Yazen Health), a Swedish digital healthtech company established in 2021. Prior to Yazen, Meurling built a track record across digital healthcare and business leadership, serving as CEO of Vital T and as Chief Financial Officer at Docly Healthcare. Under his leadership, Yazen has scaled beyond Sweden into broader European markets, securing venture funding to expand its digital weight-management platform globally

Laura Bejtulai is a strategic advisor with over a decade of experience in finance and innovation, advising life science and tech companies on fundraising, investment readiness and scaling operations. Fractional chief of staff to deeptech founders, board member, and expert evaluator for European impact investment programmes, assessing health innovation. As a former accelerator manager, she has helped launch and commercialise new ventures in life science. She is passionate about advancing women’s health and is an advocate for responsible and ethical AI.

Mads Tang-Christensen has been Chief Scientific Officer at Antag Therapeutics since 2022 and has more than 20 years of leadership experience in obesity and metabolic disease research. He previously held several leadership roles at Novo Nordisk, most recently as Corporate Vice President and Global Head of Obesity and Liver Disease. Mads co-founded Gubra and Rheoscience and is a Professor of Physiology at Monash University in Melbourne. He holds an MD and a PhD in Neurobiology from the University of Copenhagen.